Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
J Cell Sci ; 126(Pt 20): 4707-20, 2013 Oct 15.
Article in English | MEDLINE | ID: mdl-24006261

ABSTRACT

Matrix metalloproteinases (MMPs), in particular MMP-2, MMP-9 and MMP-14, play a key role in various aspects of cancer pathology. Likewise, ADAMs (a disintegrin and metalloproteinases), including ADAM12, are upregulated in malignant tumors and contribute to the pathology of cancers. Here, we show that there is a positive correlation between MMP-14 and ADAM12 expression in human breast cancer. We demonstrated that in 293-VnR and human breast cancer cells expressing ADAM12 at the cell surface, endogenous MMP-14 was recruited to the cell surface, resulting in its activation. Subsequent to this activation, gelatin degradation was stimulated and tumor cell apoptosis was decreased, with reduced expression of the pro-apoptotic proteins BCL2L11 and BIK. The effect on gelatin degradation was abrogated by inhibition of the MMP-14 activity and appeared to be dependent on cell surface αVß3 integrin localization, but neither the catalytic activity of ADAM12 nor the cytoplasmic tail of ADAM12 were required. The significance of ADAM12-induced activation of MMP-14 was underscored by a reduction in MMP-14-mediated gelatin degradation and abolition of apoptosis-protective effects by specific monoclonal antibodies against ADAM12. Furthermore, orthotopic implantation of ADAM12-expressing MCF7 cells in nude mice produced tumors with increased levels of activated MMP-14 and confirmed that ADAM12 protects tumor cells against apoptosis, leading to increased tumor progression. In conclusion, our data suggest that a ternary protein complex composed of ADAM12, αVß3 integrin and MMP-14 at the tumor cell surface regulates the function of MMP-14. This interaction might point to a novel concept for the development of MMP-14-targeting drugs in treating cancer.


Subject(s)
ADAM Proteins/metabolism , Breast Neoplasms/enzymology , Breast Neoplasms/pathology , Gelatin/metabolism , Matrix Metalloproteinase 14/metabolism , Membrane Proteins/metabolism , ADAM Proteins/immunology , ADAM12 Protein , Animals , Antibodies, Monoclonal/immunology , Antibodies, Monoclonal/pharmacology , Apoptosis/drug effects , Apoptosis/physiology , Cell Growth Processes/physiology , Cell Line, Tumor , Female , HEK293 Cells , Heterografts , Humans , Integrin alphaVbeta3/metabolism , MCF-7 Cells , Matrix Metalloproteinase 2/metabolism , Membrane Proteins/immunology , Mice , Mice, Inbred NOD
2.
Traffic ; 13(11): 1532-46, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22882974

ABSTRACT

ADAM12 (A Disintegrin And Metalloprotease 12), a member of the ADAMs family of transmembrane proteins, is involved in ectodomain shedding, cell-adhesion and signaling, with important implications in cancer. Therefore, mechanisms that regulate the levels and activity of ADAM12 at the cell-surface are possibly crucial in these contexts. We here investigated internalization and subsequent recycling or degradation of ADAM12 as a potentially important regulatory mechanism. Our results show that ADAM12 is constitutively internalized primarily via the clathrin-dependent pathway and is subsequently detected in both early and recycling endosomes. The protease activity of ADAM12 does not influence this internalization mechanism. Analysis of essential elements for internalization established that proline-rich regions in the cytoplasmic domain of ADAM12, previously shown to interact with Src-homology 3 domains, were necessary for proper internalization. These sites in the ADAM12 cytoplasmic domain interacted with the adaptor protein growth factor receptor-bound protein 2 (Grb2) and knockdown of Grb2 markedly reduced ADAM12 internalization. These studies establish that internalization is indeed a mechanism that regulates ADAM cell surface levels and show that ADAM12 internalization involves the clathrin-dependent pathway and Grb2.


Subject(s)
ADAM Proteins/metabolism , Clathrin/metabolism , Endocytosis , GRB2 Adaptor Protein/metabolism , Membrane Proteins/metabolism , ADAM Proteins/analysis , ADAM Proteins/chemistry , ADAM12 Protein , Breast Neoplasms/chemistry , Breast Neoplasms/enzymology , Carcinoma/chemistry , Endosomes/metabolism , Female , GRB2 Adaptor Protein/analysis , HEK293 Cells , Humans , Membrane Proteins/analysis , Membrane Proteins/chemistry , Proline-Rich Protein Domains , Protein Interaction Domains and Motifs
3.
PLoS One ; 7(5): e37628, 2012.
Article in English | MEDLINE | ID: mdl-22662180

ABSTRACT

A recently identified breast cancer-associated mutation in the metalloprotease ADAM12 alters a potential dileucine trafficking signal, which could affect protein processing and cellular localization. ADAM12 belongs to the group of A Disintegrin And Metalloproteases (ADAMs), which are typically membrane-associated proteins involved in ectodomain shedding, cell-adhesion, and signaling. ADAM12 as well as several members of the ADAM family are over-expressed in various cancers, correlating with disease stage. Three breast cancer-associated somatic mutations were previously identified in ADAM12, and two of these, one in the metalloprotease domain and another in the disintegrin domain, were investigated and found to result in protein misfolding, retention in the secretory pathway, and failure of zymogen maturation. The third mutation, p.L792F in the ADAM12 cytoplasmic tail, was not investigated, but is potentially significant given its location within a di-leucine motif, which is recognized as a potential cellular trafficking signal. The present study was motivated both by the potential relevance of this documented mutation to cancer, as well as for determining the role of the di-leucine motif in ADAM12 trafficking. Expression of ADAM12 p.L792F in mammalian cells demonstrated quantitatively similar expression levels and zymogen maturation as wild-type (WT) ADAM12, as well as comparable cellular localizations. A cell surface biotinylation assay demonstrated that cell surface levels of ADAM12 WT and ADAM12 p.L792F were similar and that internalization of the mutant occurred at the same rate and extent as for ADAM12 WT. Moreover, functional analysis revealed no differences in cell proliferation or ectodomain shedding of epidermal growth factor (EGF), a known ADAM12 substrate between WT and mutant ADAM12. These data suggest that the ADAM12 p.L792F mutation is unlikely to be a driver (cancer causing)-mutation in breast cancer.


Subject(s)
ADAM Proteins/genetics , ADAM Proteins/metabolism , Breast Neoplasms/enzymology , Breast Neoplasms/genetics , Membrane Proteins/genetics , Membrane Proteins/metabolism , Mutation , ADAM Proteins/chemistry , ADAM12 Protein , Cell Membrane/metabolism , Cell Proliferation , Female , Gene Expression Regulation, Neoplastic , HEK293 Cells , Humans , Membrane Proteins/chemistry , Protein Interaction Domains and Motifs/genetics , Protein Transport , Proteolysis
4.
Exp Cell Res ; 317(2): 195-209, 2011 Jan 15.
Article in English | MEDLINE | ID: mdl-20951132

ABSTRACT

Invadopodia are dynamic actin structures at the cell surface that degrade extracellular matrix and act as sites of signal transduction. The biogenesis of invadopodia, including the mechanisms regulating their formation, composition, and turnover is not entirely understood. Here, we demonstrate that antibody ligation of ADAM12, a transmembrane disintegrin and metalloprotease, resulted in the rapid accumulation of invadopodia with extracellular matrix-degrading capacity in epithelial cells expressing the αvß3 integrin and active c-Src kinase. The induction of invadopodia clusters required an intact c-Src interaction site in the ADAM12 cytoplasmic domain, but was independent of the catalytic activity of ADAM12. Caveolin-1 and transmembrane protease MMP14/MT1-MMP were both present in the ADAM12-induced clusters of invadopodia, and cholesterol depletion prevented their formation, suggesting that lipid-raft microdomains are involved in the process. Importantly, our data demonstrate that ADAM12-mediated ectodomain shedding of epidermal growth factor receptor ligands can occur within these invadopodia. Such localized growth factor signalling offers an interesting novel biological concept highly relevant to the properties of carcinoma cells, which often show upregulated ADAM12 and ß3 integrin expression, together with high levels of c-Src kinase activity.


Subject(s)
ADAM Proteins/metabolism , Actins/metabolism , Cell Membrane/metabolism , Extracellular Matrix/metabolism , Membrane Proteins/metabolism , ADAM Proteins/genetics , ADAM12 Protein , Actins/genetics , Caveolin 1/genetics , Caveolin 1/metabolism , Cell Line , Cell Membrane/genetics , Extracellular Matrix/genetics , Humans , Integrin alphaVbeta3/genetics , Integrin alphaVbeta3/metabolism , Kidney/cytology , Matrix Metalloproteinase 14/genetics , Matrix Metalloproteinase 14/metabolism , Membrane Proteins/genetics , Protein Binding/genetics , Receptors, Vitronectin/metabolism , Signal Transduction/genetics , Transfection , src-Family Kinases/genetics , src-Family Kinases/metabolism
5.
Exp Cell Res ; 316(1): 55-67, 2010 Jan 01.
Article in English | MEDLINE | ID: mdl-19769962

ABSTRACT

ADAM12 is an active metalloprotease playing an important role in tumour progression. Human ADAM12 exists in two splice variants: a long transmembrane form, ADAM12-L, and a secreted form, ADAM12-S. The subcellular localization of ADAM12-L is tightly regulated and involves intracellular interaction partners and signalling proteins. We demonstrate here a c-Src-dependent redistribution of ADAM12-L from perinuclear areas to actin-rich Src-positive structures at the cell periphery, and identified two separate c-Src binding sites in the cytoplasmic tail of ADAM12-L that interact with the SH3 domain of c-Src with different binding affinities. The association between ADAM12-L and c-Src is transient, but greatly stabilized when the c-Src kinase activity is disrupted. In agreement with this observation, kinase-active forms of c-Src induce ADAM12-L tyrosine phosphorylation. Interestingly, ADAM12-L was also found to enhance Src kinase activity in response to external signals, such as integrin engagement. Thus, we suggest that activated c-Src binds, phosphorylates, and redistributes ADAM12-L to specific sites at the cell periphery, which may in turn promote signalling mechanisms regulating cellular processes with importance in cancer.


Subject(s)
ADAM Proteins/metabolism , Actin Cytoskeleton/metabolism , Cell Membrane/metabolism , Membrane Proteins/metabolism , Protein-Tyrosine Kinases/metabolism , Proto-Oncogene Proteins/metabolism , ADAM Proteins/genetics , ADAM12 Protein , Binding Sites/physiology , Binding, Competitive , CSK Tyrosine-Protein Kinase , Cell Line , Cell Nucleus/metabolism , Cytoskeleton/metabolism , Epidermal Growth Factor/genetics , Epidermal Growth Factor/metabolism , Focal Adhesions/metabolism , Humans , Integrin alphaVbeta3/genetics , Integrin alphaVbeta3/metabolism , Membrane Proteins/genetics , Models, Biological , Mutation/physiology , Peptide Fragments/metabolism , Phosphorylation/physiology , Protein Binding/physiology , Protein Transport , Protein-Tyrosine Kinases/genetics , Proto-Oncogene Proteins/genetics , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Transfection , Vitronectin/metabolism , src Homology Domains/physiology , src-Family Kinases
SELECTION OF CITATIONS
SEARCH DETAIL
...